Kailera Therapeutics: The record-breaking obesity IPO big pharma cannot ignore
MSN·- Kailera Therapeutics trades 29 % below its IPO high while holding $1.17 billion in cash and a $42 analyst consensus price target. - Merck and Novo Nordisk emerge as natural buyers for Kailera's GLP - 1 pipeline due to impending revenue challenges and market defense needs. - Any potential acquirer will secure global rights across the U.S., Europe, and Japan while inheriting significant financial obligations.AstraZeneca: Volrustomig Setback Offset by Oncology Pipeline Strength; Buy Rating and 16,500 GBp Price Target Maintained
Tip Ranks·- Bank of America Securities analyst Sachin Jain maintained a buy rating on AstraZeneca with a target price of 16,500 pence. - The rating is supported by strong oncology performance and pipeline catalysts that offset the setback of the Phase III trial failure of volrustomig. - Jefferies also maintained a buy rating on the stock with a target price of 175.00 pounds in a separate report.